Reaching the customer
Three different selling motions, and confusing them is a common way this kind of entry fails.
Three different motions, and confusing them is a common way this kind of entry fails.
Line A sells on cost and reliability to procurement at branded manufacturers and private-label distributors. Long qualification, low differentiation, contracts renegotiated annually. A small commercial team is sufficient, and the sale is won in the plant audit rather than in the meeting.
Line B sells on capability to engineering and program management at pharmaceutical and diagnostics companies, typically 18 to 30 months before their product launches. This requires a technical sales organization that MERIDIAN's current smartphone business does not have and cannot repurpose, because the buyer is a drug-delivery program manager rather than a component buyer. It is also where the de-noising work earns its place: it does not constitute a product, since artifact rejection is solved in the analog front-end chip or in the customer's software, but it is a reason to be invited into a module conversation rather than a component one.
A qualification on who the buyer actually is. A large part of this spend does not go directly from the drug owner to a component supplier. It flows through a device platform company such as Ypsomed, or through a contract integrator such as Phillips-Medisize or Arterex, which then buys the electronics. On those programs MERIDIAN is a second-tier supplier selling to another manufacturer rather than to the brand.
That has two consequences the plan has to carry. The commercial motion is partly business development with a handful of platform companies rather than direct selling to many pharmaceutical programs, which is a smaller and more concentrated sales effort. And a second-tier position sits one step further from the price the end customer pays, which argues that the 28% gross margin modeled for this line is optimistic rather than cautious. It is left at 28% because the sensitivity table shows the verdict does not turn on it, but a reader should know which way the pressure runs.
Line C sells on qualification record and joint development to a handful of named accounts, over years. Almost entirely relationship-led, and the existing neurostimulation discussion and KAIST project are the assets.
Geography follows the brief: North America and Europe first. That is where the device makers and the reimbursement are, and it is also where the regulatory requirement is strictest.